SynapDx raises $9 million

Globe Staff

SynapDx Corp., a new company focused on developing and commercializing diagnostic testing for the early detection of autism, today announced the completion of a $9 million round of financing by Bain Capital Ventures, General Catalyst Partners, and North Bridge Venture Partners.

“Autism has a profound effect on children and their families,” Stanley N. Lapidus, the company’s founder, president and chief executive, said in a release. “The right objective blood-based diagnostic test for autism may help achieve earlier diagnosis, more rapid intervention, and improved outcomes.”

SynapDx is based in Waltham.